Network-1 Technologies reports results from Phase 2B study of BPZE1 vaccine

Network-1 Technologies announced that ILiAD Biotechnologies reported the first-ever demonstration of protection against B. pertussis colonization in a Phase 2b Human Challenge study of its BPZE1 vaccine. ILiAD announced that its BPZE1 intranasal pertussis vaccine has met the primary endpoint of protection against nasopharyngeal B. pertussis colonization in the Phase 2b CHAMPION-1 Study. To date, Network-1 has invested an aggregate of $7M in ILiAD which represents approximately 6.8% of the outstanding units of ILiAD on a non-fully diluted basis.